The combination of Tnfsf9 overexpression by tumor cells and rIL-12 nearly doubled (~70% versus 40%, respectively) the proportion of long-term survivors compared with Tnfsf9 overexpression alone. This evidence concerns the gene TNFSF9 and neoplasm.